


A /concluded-

3197	Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X
3205	Phe(C3)-Cys*-Phe-(D)Trp-Lys-Thr-Cys*-Phe(N3)-X
3207	(D)Phe-Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X
3229	Galactose-Dab*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X

On page 22, please replace the paragraph beginning with "Another preferred embodiment" with the following paragraph:

Another preferred embodiment has the general formula:



Formula No. 14

wherein m and n are 1 to 5;

X designates a terminal carboxy acid, amide or alcohol group;

R⁴ is (D)- or (L)-Phe or Tyr;

R⁶ is (D)- or (L)-Phe or Tyr;

R⁷ is (D)- or (L)-Trp, (D)- or (L)-Phe, (D)- or (L)- 1Nal or (D)- or (L)- 2Nal, or
Tyr;

R¹⁰ is Thr, Gly, Abu, Ser, Cys, Val, (D)- or (L)-Ala, or (D)- or (L)-Phe;


R¹¹ is (D)- or (L)-Phe or (D)- or (L)-Ala;

R¹² is Gly, Val, (D)- or (L)-Phe or is absent; and

Y² is thioether, thioester or disulfide.

On page 23, please replace the paragraph starting with "Another more preferred embodiment" with the following paragraph:

Another more preferred embodiment has the general formula:



Formula No. 15

wherein m and n are 1 to 5;

X designates a terminal carboxy acid, amide or alcohol group;

(X) crossed out

R⁵ is (D)- or (L)-Phe or (D)- or (L)-Ala;

R⁷ is (D)- or (L)-Trp, (D)- or (L)-Phe, (D)- or (L)-1Nal or (D)- or (L)-2Nal, or
Tyr;

R¹⁰ is Thr, Gly, Abu, Ser, Cys, Val, (D)- or (L)-Ala, or (D)- or (L)-Phe;

R¹² is Gly, Val, (D)- or (L)-Phe or is absent;

R¹³ is (D)- or (L)-Phe or (D)- or (L)-Ala; and

Y² is amide, thioether, thioester or disulfide.

Page 26, please replace old Table 3 with the following new Table 3:

Table 3. The most preferred analogs.

PTR	Sequence
3171	Phe*-Phe-Phe-(D)Trp-(D)Lys-Phe(C2)-X
3113	Phe(C1)-Phe-Phe-(D)Trp-Lys-Phe(N2)-X
3123	Phe(C1)-Phe-Phe-(D)Trp-(D)Lys-Phe(N2)-X
3209	Phe(N2)-Tyr-(D)2Nal-Lys-Val-Gly(C2)-Thr-X
3183	Phe(N2)-Tyr-(D)Trp-Lys-Val-Gly(C2)-2Nal-X
3185	Phe(N2)-Tyr-(D)Trp-Lys-Val-Val-Gly(C2)-X
3201	Phe(N2)-Tyr-(D)Trp-Lys-Ser-2Nal-Gly(C2)-X
3203	Phe(N2)-Phe-(D)Trp-Lys-Thr-2Nal-Gly(C2)-X
3173	GABA*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X
3197	Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X
3205	Phe(C3)-Cys*-Phe-(D)Trp-Lys-Thr-Cys*-Phe(N3)-X
3207	(D)Phe-Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X
3229	Galactose-Dab*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X

IN THE CLAIMS:

A marked version of the claims showing the amendments is attached hereto as
Appendix B.

Please amend Claims 13, 14, and 15 to read as follows:

13. The backbone cyclized somatostatin analog of claim 1 having the general formula
15: